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Abstract: Reduced levels of nutritional vitamin D are commonly observed in most chronic kidney
disease (CKD) patients and particularly in patients who have received a kidney transplant (KTx).
In the complex clinical scenario characterizing the recipients of a renal graft, nutritional vitamin D
deficiency has been put in relation not only to the changes of mineral and bone metabolism (MBM)
after KTx, but also to most of the medical complications which burden KTx patients. In fact, referring
to its alleged pleiotropic (non-MBM related) activities, vitamin D has been claimed to play some role
in the occurrence of cardiovascular, metabolic, immunologic, neoplastic and infectious complications
commonly observed in KTx recipients. Furthermore, low nutritional vitamin D levels have also been
connected with graft dysfunction occurrence and progression. In this review, we will discuss the
purported and the demonstrated effects of native vitamin D deficiency/insufficiency in most of the
above mentioned fields, dealing separately with the MBM-related and the pleiotropic effects.
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1. Introductory Notes
Vitamin D has long been recognized as one of the main factors involved in the regulation of
calcium and phosphorus metabolism and in the development and maintenance of the structure and
function of the musculo-skeletal system [1–3].
In humans the body pool of vitamin D is mainly supplied by its endogenous synthesis which
occurs in the skin, and by diet contribution [4].
The endogenous pathway begins in the liver where pro-vitamin D (7-dehydrocholesterol) is
synthesized from cholesterol; thereafter, 7-dehydrocholesterol is transformed in pre-vitamin D3
(cholecalciferol) in the skin under exposure to UVB light. The endogenous pathway, which is the
major source of vitamin D, supplies only vitamin D3, while dietary sources can supply either vitamin
D2 (ergocalciferol), mainly contained in plant products, or vitamin D3, contained in animal derived
foods (fish, meat, dairy products) [2,4]. The native forms of vitamin D are first converted to 25(OH)D
(calcidiol/calcifediol) in the liver which circulates in the blood, mainly bound to a specific binding
protein (DBP) and by a far lesser extent to albumin. Then, 25(OH)D is hydroxylated at the 1-α position
in the kidney by a specific hydroxylase (CYP27B1) and converted into the most active natural vitamin
D metabolite (1,25(OH)2D, calcitriol). Calcitriol is then secreted in the general circulation and reaches
its main target organs (intestine, bone, and parathyroid cells), where it exerts its biological classical
effects related to the mineral and bone metabolism, through both the genomic (action at specific
vitamin D responsive sequences of DNA) and non-genomic (direct effects at cytoplasmic membrane
and intra-cytosolic levels) pathways after binding with specific vitamin D receptors (VDR) and possibly
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other less defined receptors [5]. In recent decades, many experimental studies clearly demonstrated
that both the synthesis of active vitamin D and the expression of VDR are not confined to the kidney
and its target organs, respectively, but are also present in many other tissues [6–8]. Consequently,
there was an increasing awareness that vitamin D metabolites have not only an endocrine role mainly
devoted to the MBM control, but it might also play some additional paracrine and autocrine functions
which are very likely the basis for explaining the great number of pathophysiological effects related to
conditions different from the MBM-related vitamin D-dependent effects [9,10]. In fact, a great number
of studies have suggested that low levels of vitamin D might increase the risk of cancer, diabetes
mellitus, infections, autoimmune and immune related disorders, cardiovascular (CV) diseases and
even the mortality rate for any cause [11–16].
Though calcitriol is a much more potent vitamin D metabolite than calcidiol, the circulating levels
of the latter are considered to be the most reliable index of global vitamin D status.
Renal transplantation (KTx), though with good reason considered to be the best therapeutic
option for patients with a terminal stage of renal disease, is burdened with many complications related
to immune-mediated, CV, neoplastic, infective, musculoskeletal and metabolic problems which still
threaten the survival of both the patient and the graft and negatively impact on the quality of life
of the KTx recipients. Since vitamin D has been claimed to be potentially involved in all the above
listed pathological conditions through its classical and non-MBM related effects, there is no wonder
that a great number of papers, focused on the possible impact of vitamin D status on the clinical
complications and outcomes in the KTx patients, have been published in recent years.
The main aim of the present review is to critically analyze how much of the alleged effects of
vitamin D status in most of the above mentioned fields can be reliably accepted as certain, on the
basis of the most recent evidence. We have limited ourselves to dealing with native (nutritional)
vitamin D. In particular we have focused on the most recently published evidence which support or
contradict the alleged functions of nutritional vitamin D in the KTx clinical setting. For this purpose,
in addition to the basic references on these topics, we performed a systematic search (pubmed) of all
the papers published in the last ten years which specifically addressed the defined topics, favoring the
interventional studies, metanalyses, recent systematic reviews and statistically robust observational
studies (as agreed by all three authors of the present review).
Before addressing the issue of vitamin D status in KTx patients, one cannot help but face the
limitations in defining the condition of sufficiency of vitamin D both in the general population and,
more relevantly for the present paper, in the KTx recipients.
2. Limitations in the Assessment of Vitamin D Status
Given that the evaluation of the vitamin D status is based on the assessment of serum levels
of 25-OHD, the first limitation is related to the different laboratory methods used in the published
studies. In fact, although the most easily available and cheapest methods (automated immunoassays)
have experienced a marked improvement, their validation in comparison with the most standardized
methodologies (HPLC, liquid chromatography-tandem mass spectrometry, radioimmunoassay) is far
from being completely and satisfyingly achieved [17–19].
Second, there is great variability in vitamin D levels among different populations or individuals
of different ancestral characteristics, due to both genetic and geographical differences [20–23].
Considering that black Americans have lower levels of vitamin D than white Americans and
that different genetic polymorphisms can explain approximately 10% of vitamin D levels [23],
the prevalence of vitamin D deficiency could be consistently different in cohorts of subjects from
different countries. Furthermore, in the same individuals vitamin D status can change over time due
to seasonal variations or to modifications of the lifestyle behaviours (outdoor or indoor activity) [24].
This aspect is particularly relevant in KTx recipients, given the usual prescription of avoiding sun
exposure and/or using sunscreens with high protection levels for reducing skin cancer risk.
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Third, it still remains to be fully clarified whether the total or the free (unbound to carrier proteins)
circulating 25(OH)D should be considered as the reference of the vitamin D status and hence measured.
In fact, it is well recognized that vitamin D circulates mainly bound to DBP and to a far lesser extent
to albumin, with its free circulating fraction representing only 0.1% of the total circulating amount.
Since it is well recognized that vitamin D activity is mainly dependent on its free form, it has been
suggested that vitamin D status should be based on the assessment of the free fraction and not of
the total circulating vitamin D. This point could be of particular relevance in KTx patients, given the
potential reduced synthesis of DBP by the liver, due to the catabolic effects of some immunosuppressive
drugs (steroids, calcineurin inhibitors, mycophenolate, mTOR) or to the urinary loss of this protein
in the presence of relevant proteinuria. However, there are still many unsolved problems regarding
the dosage of DBP and of free fraction of vitamin D. Thus, given the relatively good relationship
between the free and the total fraction of vitamin D, we can continue to rely on the measurement of
the latter [25,26].
A fourth limitation in the assessment of vitamin D status is related to the uncertainties regarding
which parameters are informative of the real sufficiency of vitamin D status, thus enabling us to define
the requested threshold levels for maintaining vitamin D effects in the “normal” range. It has been
suggested that the vitamin D levels that prevent the PTH increase and/or the change in bone status,
as assessed by bone histology and/or bone mineral density (BMD) assessment, and/or the occurrence
of fractures, can be defined as sufficient. However, great controversy exists on these criteria which
have been recently challenged by some authors, since they could push up the threshold of sufficiency,
while a more physiological approach should rely on the vitamin D levels associated with the estimated
average requirements (EAR) which avoids the above listed clinical outcome [24,27–29]. For all these
reasons, there is still disagreement on what should be considered “normal” vitamin D levels, with some
authors considering 30 ng/mL as the minimal acceptable concentration, while other authors think that
the minimal acceptable threshold of 20 ng/mL could be more appropriate, in agreement with more
recent statements from the Institute of Medicine (IOM) [30].
On the other hand, the biochemical and clinical criteria for defining a sufficient vitamin D status
in the general population are particularly poorly (if at all) informative in the KTx population. In fact,
KTx patients often have high PTH levels, an altered bone status and an abnormally high occurrence of
fractures mainly as the consequence of their previous (long) history of renal failure [31].
The definition of the sufficiency level of vitamin D became even more confusing with the
increasing awareness that vitamin D can play some as yet undefined role also in other non-MBM
related physiological processes. At the present time, it is impossible even only to speculate what might
be the levels of vitamin D requested for ensuring the supposed non-MBM related effects.
3. Epidemiology of the Vitamin D Status in KTx Recipients
The information on the vitamin D status in the recipients of a renal graft is based on relatively
few and incomplete studies. In Table 1 we have summarized the main results of those studies which
reported on the prevalence of the native vitamin D status in different cohorts of KTx patients [32–45].
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Table 1. Original studies reporting data relative to the native vitamin D status in KTx patients.
References N/tot Gender M % Ethnicity % Age Years m± sdor (R) or (IQR) KTx Vintage Years m± sd or (R) or (IQR) Country
Vitamin D Status % of Patients
According to 25(OH)D Levels (ng/mL)
[33] 31/n.r. 54.8 n.s. (R 10–75) 7 (R 0.5–19) Germany
48.3% < 15
48.5% 15–30
3.2% > 30
[34] 419/n.r. 62.8 n.s. 51.0 ± 15 7.2 ± 6.4 Canada
27.2% < 16
48.2% 16–30
24.5% > 30
[35] 112/134 64.0
Cauc 64.3
51.6 ± 13.1 Assessed at time of KTx United States
28.6% < 10
AA 24.1 58.9% 10–29
Other 11.6 24.5% > 30
[36] 244/320 61.9
Cauc 95
46.1 (R 21–76)
Short term (N. 104) 0.28 (R 0.16–0.98)
United Kingdom
68% < 16
29% 16–30
Asian 3.7
3% > 30
Long term (N. 140) 6.0 (R 1–24)
51% < 16
Black 1.3
43% 16–30
6% > 30
[37] 173/242 49.9
Cauc 91
53.4 ± 11.7 7.4 (IQR 3.3–12.7) Denmark
51% < 16
29% 16–30
Black 9 20% > 30
[38] 111/n.r. 58.8 n.s. 50.5 ± 11.5 6.7 ± 5.1 Italy 69.1% ≤ 3021.9% > 30
[39] 331/389 61.6 n.s. 52.2 ± 14.1 n.r. Spain
28.7% < 16
48.6% 16–29
22.7% > 29
[40] 634/n.r. 58.7 n.s. 48.3 ± 13.4 n.r. France
54.9% < 15
36.8% 15-30
8.3% > 30
[41] 331/717 51.1
Cauc 85.8
51 (IQR 41.5–60.2) 6.7 (IQR 2.9–10.8) Canada
45.3% ≤ 30
Other 14.2 54.7% > 30
[42] 351/1211 63
AA 22
52.3 ± 13.6 n.r. United States 61.5% ≤ 20Other 78 38.5% > 20
[43] 264/n.r. 61.3 n.s. 49.0 ± 12.3 10.4 (R 2–18) Japan
24.2% < 12
44.7% 12–20
31.1% > 20
[44] 444/1083 60.6
Cauc 89.2
50.9 ± 13.7 4.0 (R 0–11) France
19.8% < 10
59.5% 10–30
Other 10.8 20.7% > 30
[45] 435/847 51 n.s. 52 ± 12 6.3 (IQR 3.1–11.7) The Netherlands
49% < 20
33% 20–30
18% > 30
Footnotes: N/tot = KTx patients included in the study/overall KTx cohort; M = male patients; n.r. = not reported; n.s. = not specified; m ± sd = mean ± standard deviation; R = range;
IQR = interquartile range; Cauc = Caucasian; AA = Afro-American.
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Notwithstanding the quite variable criteria used for the categorization of the deficiency/insufficiency
status, it appears quite evident that most KTx patients have moderately or even severely depressed
levels of native vitamin D. In particular, some cohorts which included a consistent proportion
of Afro-American (AA) patients [35] or were from countries with little sun exposure [36] were
characterized by a very limited percentage of patients with sufficient levels of vitamin D, however
defined, with only 12% or 3–6% of the overall patients having vitamin D levels above 30, respectively.
Furthermore, in one of these studies from England [36], including 244 KTx recipients, where 104 of
them had received a KTx less than one year previously while the remaining 140 were long-term KTx
recipients, the authors found that moderate (calcifediol between 15 and 5) and severe (calcifediol of <5)
vitamin D deficiency was more frequently found in the short term group as opposed to the long-term
group. Overall, only 3% of the short term and 6% of the long-term KTx recipients had sufficient
levels of vitamin D [36]. It is also worth underlining that some difference among the cohorts could be
explained by a different attitude of the transplant centers to use vitamin D supplementation. In fact,
in a cross-sectional study from a Danish group, including 173 KTx patients, a slightly lower percentage
of patients with vitamin D deficiency (29%) was reported [37]; however, 69% of women and 51%
of men in this KTx cohort received vitamin D supplements. In fact, in a more recent study from
Canada, performed in 331 KTx patients, the authors found that vitamin D insufficiency/deficiency
(calcifediol of <30 ng/mL) was present in 35.2% and 76.5% of KTx patients who received or did not
receive vitamin D supplements, respectively [41].
In addition to the conditions discussed above, many other factors can contribute to the variability
in the reported prevalence of vitamin D deficiency/insufficiency in the different cohorts of KTx
patients [32,41] (see Table 2). Among them, proteinuria deserves more discussion. In fact, urinary
protein loss, which occurs with a certain frequency in KTx patients, is almost invariably associated
with the loss of DBP in urine. This could be at least in theory followed by a reduction of the
circulating levels of the DBP and of its specific ligand, namely vitamin D, increasing the occurrence of
a deficiency/insufficiency status [46] However, the reduction of the total circulating amount does not
necessarily translate into a real deficiency/insufficiency condition, since the free (active) fraction of
vitamin D can still remain within the normal range. Furthermore, even the fall in the total circulating
amount of vitamin D has been recently questioned by Doorenbos and coworkers [47], who, though
confirming that proteinuria is invariably associated with a consistent urinary loss of the DBP, have not
observed any significant change in both DBP and vitamin D total or free circulating levels.
Table 2. Factors which can play a role in the different prevalence of the vitamin D deficiency/insufficiency
status in KTx patients (neg = increases the risk for the finding of low total vitamin D levels;
pos = reduces the risk for the finding of low vitamin D levels; BMI = body mass index; KTx = kidney
transplantation) [32,41,46,47].
Factor Characteristics Type of Effect
Ethnicity Afro-Americans neg
Age Elderly neg
Gender Women neg
BMI High neg
Smoking Yes neg
Sun exposure Yes pos
Dietary intake/VitD supplements Yes pos
Diabetes Yes neg
Liver dysfunction Yes neg
Urinary protein High neg (?)
Time from KTx Early neg
Steroid doses High neg
The available epidemiological data show that low levels of vitamin D are frequently found in KTx
patients and supplementation with native vitamin D can improve, though only to a limited extent,
the vitamin D insufficient/deficient status.
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4. Vitamin D Status and Mineral and Bone Disease in KTx
It is well known that the derangements of mineral (MM) and bone metabolism are frequent
complications in KTx patients [48,49]. In fact, persistent secondary hyperparathyroridism (PSHP) is
frequently observed after KTx and it has been claimed to be one of the causal factors for the increased
incidence of skeletal fractures in KTx recipients [31,50,51]. Furthermore, PSHP of KTx patients is
frequently associated with hypercalcemia, which has been suggested to contribute to both graft
dysfunction and progression of vascular calcifications in such patients [52,53].
It is widely recognized that the reduced bioavailability of vitamin D can directly and indirectly
stimulate PTH production, negatively affecting the musculoskeletal system [34,54,55].
Given the reported high prevalence of vitamin D insufficiency/deficiency in KTx patients,
a priority question is related to whether and how much the deficit of native vitamin D can contribute
to the MM and bone diseases and, even more important, if its correction could positively impact on
bone health in this clinical setting.
Though the main causal factors of PSHP are related to the degree of secondary hyperparathyroidism
(SHP) preceding the KTx, a suboptimal vitamin D status might contribute in determining a higher
level of PSHP. Thus, the correction of vitamin D insufficiency/deficiency might contribute to a better
control of PSHP after KTx and possibly to an improvement of the related bone disease.
In most of the few interventional studies directed to prevent bone loss and fractures occurring
in KTx patients, the proposed therapy consisted of bisphosphonates, active vitamin D metabolites,
calcium supplements or cinacalcet [56,57].
Few studies have addressed this topic investigating the effects of native vitamin D supplementation
on the MM-related parameters and/or bone health in KTx recipients.
In a study from France, 49 KTx patients, with calcifediol levels lower than 30 ng/mL, were treated
with cholecalciferol 100,000 IU every two weeks from the fourth to the sixth month after KTx and
thereafter with 100,000 UI every other month, while 47 KTx patients with the same degree of vitamin
D insufficiency did not receive any vitamin D supplement. After one year, the calcifediol levels
significantly increased with a concomitant decrease of PTH levels in the treated group, while no
significant change was observed in the untreated patients [58]. In another study from Spain, the authors
randomised 168 KTx to receive 266 mcg of calcifediol by oral route either monthly or biweekly.
Both regimens were effective in correcting the vitamin D insufficiency in most patients with a significant
reduction of PTH [59].
In a study by Wissing and coworkers, 91 KTx patients were randomized to receive calcium
supplementation with or without the addition of a monthly dose of 25,000 IU of cholecalciferol.
Although in this study, vitamin D supplementation was also associated to a reduction of PTH levels,
no significant effect was observed as far as bone mineral loss [60].
To the best of our knowledge, there is no study which faced the issue of the possible effect of
the correction of vitamin D insufficiency on skeletal fracture occurrence. In a recent retrospective
observational study, two groups of patients who received a KTx in a single center in two different
periods of time, from 2004 to 2006 and from 2009 to 2011, were compared. The authors found
that in the group transplanted in the most recent period, vitamin D supplementation increased and
this finding was associated with a reduction in the percentage of vitamin D deficiency from 64 to
20%, and a concomitant decrease of fracture incidence from 9.1 to 3.1% [61]. However, given the
retrospective and observational design of this study it cannot be considered to be proof that vitamin D
supplementation can reduce fractures in KTx.
It is also worth considering that the doses and the schedules used for correcting vitamin D
insufficiency/deficiency were quite variable among these quoted studies, which makes it difficult to
draw any definite conclusions.
Collectively, these studies of KTx patients suggest that the correction of native vitamin D
levels could contribute to a better control of PSHP; however, no effect on bone health has yet
been demonstrated.
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5. Vitamin D Status and Potential Non-MBM Related Effects in KTx
As mentioned before, it has been suggested that vitamin D plays a role in a number of non-classical
biological pathways due to the almost ubiquitary expression of its specific receptor and to the capacity
of a great number of tissues utilizing 25(OH)D to synthesize calcitriol. In recent years, there has been
a flourishing of experimental and clinical papers suggesting a number of potentially beneficial effects
of vitamin D in a vast array of different pathological conditions. Most of these postulated effects may
play a counteracting role towards both the most common complications occurring in KTx patients and
most of the factors which concur to allograft dysfunction. It is out of the focus of the present review to
address the long list of studies (mostly experimental and observational) which dealt with the alleged
non-classical “pleiotropic” effects of vitamin D (this topic has been recently reviewed [62]).
In the following paragraphs, we will limit ourselves to summarizing the results of the studies
recently published on this topic, dealing separately with the potential effects on the general clinical
complications and those potentially affecting the graft outcome.
5.1. Potential Effects Counteracting KTx Complications
Even though KTx recipients generally achieve far better results than dialysis patients, they
are nevertheless subject to numerous complications which negatively impact on both survival and
quality of life. Among the long list of complications which can occur in KTx patients, cardiovascular,
infectious, neoplastic and metabolic diseases are the most relevant ones. In fact, a vast number of
studies suggest that vitamin D deficiency may be involved in or add to the occurrence of these clinical
events (Figure 1) [62].
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Figure 1. Suggested “non-mineral and bone metabolism (MBM) related” effects of native vitamin D
which could play a beneficial role on the main clinical complications which occur in kidney transplant
(KTx) patients. RAS = renin angiotensin system.
After the s minal study from Li and coworkers [63], who showed that vitamin D c n play
an inhibitory effect on the Renin-Angiotensin system, a number of experimental and observational studies
further supported a potentially beneficial role of vitamin D in preventing cardiovascular complications
in many clinical settings of chronic kidney diseases, including KTx (we recently revised this topic; [15]).
Another potentially beneficial effect of vitamin D in the KTx clinical setting is related to
its hypothesized protective effects against infections. As an indirect support of this hypothesis,
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in a retrospective evaluation of 89 KTx recipients, the authors found that vitamin D insufficiency
(<20 ng/mL) was associated with an increased incidence of opportunistic infections [64].
The potential impact of vitamin D levels on one of the most frequent metabolic complications
of KTx patients was recently supported by a prospective observational study carried out in a single
KTx transplant center, demonstrating that vitamin D deficiency (defined as 25(OH)D <10 ng/mL)
was found to be associated with an increased risk of occurrence of post-transplant diabetes mellitus
(PTDM) [44].
A possible link between low pre-transplant levels of native vitamin D and the risk of developing
cancer after KTx has been suggested by an observational study performed in 363 KTx patients [65].
In fact, the authors reported that the risk of cancer increased by about 12% for each ng/dl decrease
of vitamin D levels, which was double the increase of the risk associated with increasing age of the
patients (6% for each additional year).
On the other hand, recent evidence, based on randomized clinical trials and metanalysis, has
mitigated the enthusiasm about most of these alleged “pleiotropic” effects of vitamin D, since no clear
beneficial effects of vitamin D supplementation has been demonstrated on the prevention of neoplasia,
CV and/or metabolic complications in many clinical settings [39,66–71].
Thus, although many experimental and epidemiological data suggest a potentially beneficial role
of vitamin D in many pathological conditions, there is still no evidence that the correction of vitamin
D insufficiency/deficiency can improve any clinical outcome.
However, it should be stressed again that most of this evidence has been produced in clinical
conditions different from KTx, which still continues to lack consistent studies and hence of evidence.
5.2. Potential Effects Counteracting Allograft Dysfunction
One of the main and yet unsolved problems in the KTx field is related to chronic allograft
dysfunction(s) (CAD) which still represent the major limitation to graft survival in the long-term.
A large number of factors may contribute to CAD, the most relevant of which are shown in the
Figure 2. Vitamin D deficiency has been shown to be associated with most of these factors, potentially
contributing to the occurrence of CAD (darker boxes in Figure 2). Most of these potentially beneficial
effects have been dealt with in recent reviews [62,72].
Particular attention has been paid in recent years to the potential immunomodulatory effects of
vitamin D, since most of the cells involved in the innate (monocytes, dendritic cells) and in the adaptive
(T-cell, B-cell) express both CYP27B1 and VDR, indicating their capability of both synthesizing calcitriol
from 25(OH)D and of responding to its effects by autocrine/paracrine pathways, with their activity
being modulated by vitamin D. Collectively, the final effect of vitamin D on the immune system
could be the shift toward a less inflammatory and a more tolerogenic phenotype, playing a potentially
positive role on graft survival [72–76].
In a former study performed in 64 KTx patients who were submitted to protocol biopsy,
Courbebassie et al. reported no association between cholecalciferol supplementation and the histologic
(Banff scores) and functional (iohexol clearance) indices of graft function [77]
However, Bienaimé et al. subsequently studied a larger cohort of 634 KTx patients, reporting that
basal low levels of 25(OH)D were predictive of a lower glomerular filtration rate (GFR) at one year
after KTx and were associated to a greater degree of interstitial fibrosis and tubular atrophy in protocol
biopsies performed 3 and 12 months after transplantation [40].
A former study carried out in 106 KTx patients in whom a pre-transplant measurement of
25(OH)D was available, showed that vitamin D levels were significantly related to the GFR levels
during the first three years after KTx [78]. In another more recent study carried out in 435 KTx patients
followed up over a mean of seven years, Keyzer and colleagues reported that very low levels of native
vitamin D (<12 ng/mL) were associated with increased mortality and a more pronounced reduction of
GFR [45]. In the same direction, a prospective observational study performed in 264 Japanese KTx
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patients showed that vitamin D insufficiency/deficiency was associated with a higher decline of GFR
during the first 10 years after KTx, but not thereafter [43].
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Figure 2. Main factors contributing to the development of chronic renal allograft dysfunction.
The darker boxes represent mechanisms on which vitamin D status could play some counteracting role.
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Th ri k of developing an acute rejection (AR) in rel tion t vitamin D status was ev luated in
a US cohort of 351 KTx recipie ts. In this study, the authors reported that patients with vitamin D
levels of <20 ng/mL, assessed within 30 days after KTx, had a more than double risk of AR than
patients with normal vitamin D levels [42].
In an observational study on 516 KTx patients, low 25(OH)D levels were associated with worse
renal outcomes, an supplementation with cholecalciferol were associated with both better renal and
patient outcomes [79].
Collectively, all these data seem to suggest that it could be worth correcting vitamin D
insufficiency/deficiency in KTx patients. However, it should be underlined that all these studies
are observational and often retrospective studies, so their informative level is very limited. We need
to wait for the results of the few ongoing randomized controlled trials so as to be able to draw more
definitive conclusions on this issue [80–82]. However, some of these trials started a long time ago
and/or are not yet recruiting patients, so it is highly unlikely we will obtain more evidence in the
near future.
6. Conclusive Remarks
In the last few years, the renal transplant community has become more aware that native vitamin
D insufficiency/deficiency is very common in KTx recipients. Its correction can be at least in part
achieved by native vitamin D supplementation.
Though we are well aware that such a correction can contribute to a better control of the levels of
PTH, which are often elevated in these patients, the beneficial effects of this therapeutic intervention
on bone health remain to be defined.
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Even more undefined are the possible beneficial effects, if any, of the correction of vitamin D
deficits on the general medical complications often occurring in KTx recipients, as well as on the
alleged protective effect on renal grafts.
It is also worth underlining that there is still no general agreement on the optimal target of
vitamin D to be achieved, the doses which should be used, and how long the supplementation should
be maintained.
On the other hand, when using any vitamin D metabolite in KTx recipients we should also
be aware of the risk of inducing hypercalcemia which could be more frequent than in the general
population. In fact, KTx patients are more prone to developing hypercalcemia, due to the synergistic
effects of the PTH levels being disproportionately high compared to the renal function, associated with
the often low phosphorus levels and the increased sensitivity of bone and intestine to PTH and vitamin
D, respectively [52]. Hence, overzealous vitamin D repletion might be associated with an increased risk
of hypercalcemia in KTx patients with the potential risk of negatively affecting the graft function [83].
The risk of hypercalcemia could be further increased in the case of (unrecognized) polymorphic
mutations of the enzymes involved in the metabolism of vitamin D metabolites [84,85].
We still need to wait for further definitive evidence, but in the meantime we could “moderately”
correct vitamin D levels in KTx recipients while carefully monitoring serum calcium levels.
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